Expression varied according to tumour molecular phenotype with 73%, 16 and 11% Mtss1 expression seen in oestrogen receptor (ER)-positive, ER-negative and HER2+ patient classes, respectively (χ2 = 25.84, p < 0.0001). This evidence concerns the gene ERBB2 and neoplasm.